Russia is going to miss its target of making 30 million doses of an experimental Covid-19 vaccine this year due to setbacks maintaining the serum’s stability while expanding production.
“The main task is to scale up production,” Industry Minister
The Kremlin has pinned great hopes on the Sputnik V vaccine, which President
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.